Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ZTTBV |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-KIT mAb 4C9 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Mast/stem cell growth factor receptor Kit (KIT) |
Antigen Info | ||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Dissociation Constant (Kd)
|
5.5
|
nM
|
||||
|---|---|---|---|---|---|---|
| Antibody Function | Confirm the effect of the drug conjugation with the anti c-Kit mAb and ADC on binding activity to cell line. | |||||
| Antibody Antigen Binding Assay | A quantitative analysis of the binding affinity using surface plasmon resonance (SPR) was used to determine the binding affinity of 4C9 to human c-Kit. | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
4C9-DM1 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 40.00% (Day 14) | Positive KIT expression (KIT+++/++) | ||
| Method Description |
In vivo efficacy of 4C9-DM1 was examined using mouse models xenotransplanted with NCI-H526, mice with established tumors were randomized into different treatment groups when the tumor volume reached ~200 mm 3. The dose of 4C9-DM1 was 1 mg/kg twice at day 0 and day 7.
|
||||
| In Vivo Model | Small cell lung cancer CDX model | ||||
| In Vitro Model | Small cell lung cancer | Small cell lung cancer cells | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 45.00% (Day 14) | Positive KIT expression (KIT+++/++) | ||
| Method Description |
In vivo efficacy of 4C9-DM1 was examined using mouse models xenotransplanted with NCI-H526, mice with established tumors were randomized into different treatment groups when the tumor volume reached ~200 mm 3. The dose of 4C9-DM1 was 3 mg/kg twice at day 0 and day 7.
|
||||
| In Vivo Model | Small cell lung cancer CDX model | ||||
| In Vitro Model | Small cell lung cancer | Small cell lung cancer cells | Homo sapiens | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 59.00% (Day 14) | Positive KIT expression (KIT+++/++) | ||
| Method Description |
In vivo efficacy of 4C9-DM1 was examined using mouse models xenotransplanted with NCI-H526, mice with established tumors were randomized into different treatment groups when the tumor volume reached ~200 mm 3. The dose of 4C9-DM1 was 5 mg/kg twice at day 0 and day 7.
|
||||
| In Vivo Model | Small cell lung cancer CDX model | ||||
| In Vitro Model | Small cell lung cancer | Small cell lung cancer cells | Homo sapiens | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.16 nM
|
Positive KIT expression (KIT+++/++) | ||
| Method Description |
C-Kit positive or negative SCLC cell lines were seeded into 96-well plates and incubated with 4C9 or 4C9-DM1 in a dose-dependent manner for 35 days.
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H526 cells | CVCL_1569 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.32 nM
|
Positive KIT expression (KIT+++/++) | ||
| Method Description |
C-Kit positive or negative SCLC cell lines were seeded into 96-well plates and incubated with 4C9 or 4C9-DM1 in a dose-dependent manner for 35 days.
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H889 cells | CVCL_1598 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
4.08 nM
|
Positive KIT expression (KIT+++/++) | ||
| Method Description |
C-Kit positive or negative SCLC cell lines were seeded into 96-well plates and incubated with 4C9 or 4C9-DM1 in a dose-dependent manner for 35 days.
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H1048 cells | CVCL_1453 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
16.58 nM
|
Negative KIT expression (KIT-) | ||
| Method Description |
C-Kit positive or negative SCLC cell lines were seeded into 96-well plates and incubated with 4C9 or 4C9-DM1 in a dose-dependent manner for 35 days.
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H446 cells | CVCL_1562 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
35.50 nM
|
Negative KIT expression (KIT-) | ||
| Method Description |
C-Kit positive or negative SCLC cell lines were seeded into 96-well plates and incubated with 4C9 or 4C9-DM1 in a dose-dependent manner for 35 days.
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H2170 cells | CVCL_1535 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
47.63 nM
|
Negative KIT expression (KIT-) | ||
| Method Description |
C-Kit positive or negative SCLC cell lines were seeded into 96-well plates and incubated with 4C9 or 4C9-DM1 in a dose-dependent manner for 35 days.
|
||||
| In Vitro Model | Amelanotic melanoma | MDA-MB-435 cells | CVCL_0417 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.